World

NASA's Space-X Crew-6 to head home after wrapping up mission aboard space station

Aug 31, 2023

Los Angeles [US], August 31: NASA's SpaceX Crew-6 is heading home soon, wrapping up a six-month mission aboard the International Space Station (ISS), according to NASA.
The Crew-6 consists of NASA astronauts Stephen Bowen and Woody Hoburg, United Arab Emirates astronaut Sultan Alneyadi, and Roscosmos cosmonaut Andrey Fedyaev. They spent months on the orbiting lab conducting scientific investigations and technology demonstrations that help prepare humans for future space missions and benefit people back on Earth.
Crew-6 is the sixth crew rotation flight of a Dragon spacecraft as part of NASA's Commercial Crew Program.
The mission launched on March 2 from the Kennedy Space Center in Florida, and successfully docked to the ISS on March 3.
The Crew-6 carried out experiments including studies of how particular materials burn in microgravity, tissue chip research on heart, brain, and cartilage functions, and an investigation that would collect microbial samples from the outside of the space station, according to NASA.
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025